{"nctId":"NCT04541043","briefTitle":"Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)","startDateStruct":{"date":"2020-11-17","type":"ACTUAL"},"conditions":["Primary IgA Nephropathy"],"count":119,"armGroups":[{"label":"Active Nefecon treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Nefecon 16mg daily"]}],"interventions":[{"name":"Nefecon 16mg daily","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients that completed study Nef-301\n2. On a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs) at the maximum allowed dose or maximum tolerated dose according to the 2012 KDIGO guidelines\n3. Willing and able to provide written informed consent.\n4. UPCR equal to or more than 0.8 g/gram\n5. eGFR equal to or more than 30 mL/min per 1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.\n\nExclusion Criteria:\n\n1. Systemic diseases that may cause mesangial IgA deposition.\n2. Patients who have undergone a kidney transplant;\n3. Patients with presence of other glomerulopathies and/or nephrotic syndrome\n4. Patients with acute, chronic, or latent infectious disease including hepatitis, tuberculosis (TB), human immunodeficiency virus (HIV), and chronic urinary tract infections;\n5. Patients with liver cirrhosis, as assessed by the Investigator;\n6. Patients with a diagnosis of type 1 or type 2 diabetes mellitus which is poorly controlled\n7. Patients with history of unstable angina, class III or IV congestive heart failure, and/or clinically significant arrhythmia, as judged by the Investigator;\n8. Patients with unacceptable blood pressure control defined as a blood pressure consistently above national guidelines for proteinuric renal disease, as assessed by the Investigator.\n9. Patients with diagnosed malignancy within the past 5 years.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline","description":"The outcome is measured as UPCR based on 24 hour urine collections at 9 months following the first dose of Nefecon compared to baseline Ratio being: UPCR at 9 months in g/gram divided with UPCR at Baseline in g/gram","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":null},{"groupId":"OG001","value":"0.69","spread":null}]}]}]},{"type":"PRIMARY","title":"Ratio of Estimated Glomerular Filtration Rate (eGFR) at 9 Months Compared to Baseline","description":"The outcome is measured as ratio of eGFR in mL/min/1.73 m2 (calculated using the CKD-EPI formula) at 9 months following the first dose of Nefecon compared to baseline. I.e. eGFR at 9 months divided by eGFR at Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"0.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months Compared to Baseline","description":"Ratio of urine albumin to creatinine ratio (UACR) measured by 24h urine sampling at 9 months compared to baseline. I.e. UACR at 9 months divided by eGFR at Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":null},{"groupId":"OG001","value":"0.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Short Form 36 (SF-36) Quality of Life Assessment at 12 Months","description":"Short Form 36 (SF-36) quality of life assessment at 12 months compared to baseline, i.e. change from baseline.\n\nThe 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used. It consists of eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.\n\nHigher scores indicate better health. Scores represent the percentage of total possible score achieved, i.e. 0 is the minimum and 100 is the maximum score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.518","spread":"10.0522"},{"groupId":"OG001","value":"-3.756","spread":"9.9213"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.290","spread":"7.4076"},{"groupId":"OG001","value":"-3.301","spread":"5.8211"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.282","spread":"7.1270"},{"groupId":"OG001","value":"-1.061","spread":"6.6251"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.725","spread":"7.1576"},{"groupId":"OG001","value":"-1.570","spread":"6.3522"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.952","spread":"6.6367"},{"groupId":"OG001","value":"-3.403","spread":"6.1115"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.697","spread":"7.4670"},{"groupId":"OG001","value":"-1.996","spread":"6.6726"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.928","spread":"7.2390"},{"groupId":"OG001","value":"-0.747","spread":"7.4962"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.421","spread":"7.1914"},{"groupId":"OG001","value":"-2.793","spread":"7.6901"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.102","spread":"8.4631"},{"groupId":"OG001","value":"-2.364","spread":"6.3713"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.633","spread":"7.6406"},{"groupId":"OG001","value":"-2.376","spread":"7.6968"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Microhematuria at 9 Months Compared to Baseline","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Receiving Rescue Treatment","description":"Systemic immunosuppressive drugs (including glucocorticoids in some situations ), dialysis, and renal transplantation are considered as rescue medications in this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients on Dialysis, Undergoing Kidney Transplantation, or With eGFR <15 mL/Min Per 1.73 m2","description":"Looking at number of patients with end stage kidney disease defined as being on dialysis, undergoing kidney transplantation, or having eGFR \\<15 mL/min per 1.73 m2","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Cortisol Suppression at 9 Months","description":"Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.122","spread":"25.1690"},{"groupId":"OG001","value":"-32.126","spread":"30.6978"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Cortisol Suppression at 12 Months","description":"Cortisol suppression at 9 and 12 months, measured as urinary cortisol excretion over 24 hours compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.660","spread":"27.4262"},{"groupId":"OG001","value":"-11.954","spread":"25.8052"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":45},"commonTop":["Corona virus infection","Hypertension","Weight increased","Oedema peripheral","Muscle spasms"]}}}